Clarivate Plc (CLVT) SEC Filings & Earnings Calls

Loss of Life Sciences and Healthcare revenue stream; transition services risk

“Sale of entire business segment; President of that business terminated”

Deferred consideration dependent on transition services completion

“Deferred consideration payable upon completion of transition services or by Jan 31, 2028”

No material risks identified; the tender offer is a routine debt management event.

“No specific risks highlighted beyond the tender offer itself.”

Debt tender offer may indicate refinancing or balance sheet restructuring; terms not disclosed.

“Press release attached as exhibit provides pricing terms; no further details in excerpt.”

Tender offer may indicate refinancing need or balance sheet optimization; no financial details provided.

“cash tender offer for certain of its debt securities”

Goodwill impairment from LS&H divestiture

“During the second quarter of 2026, we identified indicators of impairment related to the LS&H reporting unit and performed an interim quantitative goodwill impairment assessment as of June 30, 2026. We determined the anticipated LS&H sale price under negotiation was the best estimate of fair value and, because it was below its carrying amount, resulted in a ” · word for word

Revenue decline from product wind-downs

“Revenues decreased primarily due to product group wind-downs within LS&H and A&G segments.” · word for word

Transactional revenue volatility

“Transactional revenues decreased due to product group wind-downs, primarily within A&G, as well as lower organic activity across all segments, driven in part by customer migrations to subscription offerings.” · word for word

Goodwill impairment risk from LS&H divestiture and segment wind-downs

“$221.7 million non-cash goodwill impairment charge in Q2 2026; goodwill reduced from $1,566.7M to $1,344.9M”

Organic revenue decline driven by transactional weakness and product wind-downs

“Organic revenues decreased 1.5%; transactional revenues down 30.1% (organic -15.7%) due to product group wind-downs and customer migration to subscriptions”

Free cash flow decline may pressure deleveraging pace

“Free cash flow H1 2026 $122.9M vs $160.6M prior year, down 23.5%”

Forward-looking statements highlight risks related to divestiture, use of proceeds, and macroeconomic uncertainty.

“Forward-looking statements caution about risks and uncertainties.”

Transaction subject to regulatory approvals and closing conditions; termination fee of $33M if buyer fails to close.

“Closing conditions include regulatory approvals; termination fee payable by buyer under certain circumstances.”

Key segment leadership change could disrupt IP operations, but successor's experience and smooth transition plan mitigate risk.

“Departure of President of IP segment; successor appointed with two decades of experience; separation agreement includes non-compete.”

Product wind-down execution risk

“In December 2024, our Board approved the wind-down of three product groups within the LS&H and A&G segments, which is continuing into 2026 and partially affects prior year comparability as further discussed below.” · word for word

LS&H sale process uncertainty

“We are currently engaged in active discussions with interested parties but cannot assure that the sale process will result in a transaction.” · word for word

Decline in transactional revenues due to disposals and lower activity

“Transactional revenues declined 20% YoY, reflecting impact of disposals and lower A&G activity”

High debt level despite deleveraging

“Total debt outstanding $4.33 billion; net leverage still elevated”

Intellectual Property segment underperformance

“IP Segment. Based on results for 2025, the weighted average attainment across the IP segment metrics was 48%.” · word for word

Low recurring organic revenue growth

“Recurring organic revenue growth was 0.6% in 2025.” · word for word

Significant market cap decline

“Market capitalization $2,100 (2025) vs $3,500 (2024).”

High leverage from finance lease

“The finance lease ROU asset of $8.0 million is shown on Clarivate's financial statements, and the corresponding lease liability of $28.1 million is treated as indebtedness.” · word for word

Potential retention risk if severance terms are perceived as insufficient; however, changes appear standard.

“The plan maintains substantially similar terms and conditions, except as described below.”

Goodwill Impairment Risk

“In 2024, we recorded a goodwill impairment charge of $465.7 primarily due to sustained declines in our share price and worsening macroeconomic and market conditions.” · word for word

Revenue Decline from Disposals

“Revenues decreased 4% to $2,455.2M in 2025 from $2,556.7M in 2024, primarily due to product group wind-downs and the ScholarOne and Valipat divestitures.”

Divestiture execution risk: sale of Life Sciences & Healthcare may not materialize.

“There can be no assurances that the sale process will result in a transaction.” · word for word

Revenue decline from divestitures: reported revenue lower due to strategic divestitures.

“overall reported revenue will be lower due to the previously announced strategic divestitures of transactional based revenues” · word for word

Decline in adjusted EBITDA and free cash flow year-over-year

“Adjusted EBITDA down 4.5%; free cash flow down 8.6%.”

Product Wind-Down Execution Risk

“In December 2024, our Board approved the wind-down of three product groups within the LS&H and A&G segments, which is expected to reduce revenues and profit by less than 10% and 5%, respectively.” · word for word

Goodwill Impairment Risk

“In the second quarter of 2024, primarily due to sustained declines in our share price, we performed an interim quantitative goodwill impairment assessment...resulting in a goodwill impairment charge of $302.8.” · word for word